Skin mucosa disinfectant and preparation process thereof

Abstract

The invention relates to the technical field of disinfectants, and particularly discloses a skin mucosa disinfectant and a preparation process thereof. The skin mucosa disinfectant is prepared from the following raw materials in percentage by weight: 3%-6% of povidone iodine, 0.02%-0.1% of monopotassium phosphate, 0.2%-0.4% of dipotassium phosphate, 0.02%-0.06% of chlorhexidine acetate, 1%-3% of a surfactant, 2%-4% of polyvinylpyrrolidone and the balance of purified water. According to the skin mucosa disinfectant disclosed by the invention, povidone iodine and chlorhexidine acetate are taken as effective bactericidal components, and loss of effective iodine content in a povidone iodine solution system is effectively reduced through dipotassium phosphate and monopotassium phosphate; the povidone-iodine solution system has good stability and durability in the storage process, so that the disinfectant can have good disinfection and sterilization effects when acting on an affected part.

Description

Technical Field

[0001] This application relates to the technical field of disinfectants, and more specifically, to a skin and mucous membrane disinfectant and its preparation process. Background Technology

[0002] Disinfectants are chemical agents that can kill or remove pathogenic microorganisms (such as bacteria and viruses), and are currently widely used in disinfection and hygiene protection in fields such as medicine. The main types of disinfectants on the market include halogen-based disinfectants, alcohol-based disinfectants, peroxide-based disinfectants, quaternary ammonium salt disinfectants, and phenolic disinfectants.

[0003] Among halogenated disinfectants, iodine-containing disinfectants are the most common. For example, povidone-iodine is widely used for disinfecting skin and mucous membranes. It primarily works by using the oxidation and halogenation of iodine to destroy the proteins, nucleic acids, and cell membrane structures of pathogens, thus achieving disinfection and sterilization. However, the disinfection and sterilization effect of traditional iodine-containing disinfectants is easily affected by the effective iodine content. During storage, the effective iodine content may decrease due to factors such as the volatilization of elemental iodine and the oxidation of iodide ions, thereby severely impacting the disinfection and sterilization effect of the iodine-containing disinfectant.

[0004] Therefore, there is an urgent need for a skin and mucous membrane disinfectant with good and durable disinfection and sterilization effects. Summary of the Invention

[0005] To address the issue that the disinfection and sterilization effects of traditional iodine-containing disinfectants decrease due to a reduction in effective iodine content, this application provides a skin and mucous membrane disinfectant and its preparation process. This disinfectant exhibits good stability during storage, effectively maintains the effective iodine content, and can be widely applied to disinfection and sterilization in areas such as skin and mucous membranes, possessing highly efficient and broad-spectrum bactericidal functions.

[0006] In a first aspect, this application provides a skin and mucous membrane disinfectant, which adopts the following technical solution: A skin and mucous membrane disinfectant is prepared from raw materials comprising the following components: 3%-6% povidone-iodine, 0.02%-0.1% potassium dihydrogen phosphate, 0.2%-0.4% dipotassium hydrogen phosphate, 0.02%-0.06% chlorhexidine acetate, 1%-3% surfactant, 2%-4% polyvinylpyrrolidone, and the balance being purified water.

[0007] By adopting the above technical solution, using povidone-iodine as the main disinfection and sterilization component, the aqueous solution of povidone-iodine has the characteristic of slow iodine release, which can effectively prolong the sterilization time and reduce irritation to the skin and mucous membranes. The addition of potassium dihydrogen phosphate and dipotassium hydrogen phosphate as pH buffers can maintain the povidone-iodine solution system within a suitable acidic pH range, effectively reducing the oxidation and volatilization of iodine, thereby ensuring the effective iodine content in the povidone-iodine solution system and reducing the loss of effective iodine content. Chlorhexidine acetate is added as an auxiliary bactericide to impart certain disinfection and sterilization functions to the povidone-iodine solution system. Simultaneously, the combined action of chlorhexidine acetate and surfactants can reduce the surface tension of the povidone-iodine solution system to a certain extent, allowing the disinfectant to be better adsorbed and absorbed by the affected area when applied to skin and mucous membranes, thereby achieving disinfection and sterilization. At the same time, the addition of surfactants and chlorhexidine acetate enhances the stability of the povidone-iodine solution system. This may be due to the adsorption of surfactants, forming a molecular film around the povidone-iodine molecules, thus creating a protective layer that inhibits particle collisions and sedimentation, thereby inhibiting the dissociation of iodine from povidone-iodine and reducing the aggregation or volatilization of iodine molecules. Polyvinylpyrrolidone (PVP) is added as an iodine stabilizer. PPVP can form a relatively stable complex with the dissociated iodine in povidone-iodine through charge transfer, thereby transforming iodine from a volatile free state to a bound state, thus reducing the decrease in effective iodine content. Meanwhile, polyvinylpyrrolidone contains a large number of polar groups, such as hydroxyl and carbonyl groups, which can form hydrogen bonds with water molecules, thereby increasing the solubility of iodine molecules in water and effectively preventing the aggregation and precipitation of iodine molecules, thus improving its solubility in water. The skin and mucous membrane disinfectant of this invention uses povidone-iodine and chlorhexidine acetate as effective bactericidal components. The use of dipotassium hydrogen phosphate and potassium dihydrogen phosphate effectively reduces the loss of effective iodine content in the povidone-iodine solution system. Furthermore, the addition of surfactants and polyvinylpyrrolidone ensures that the povidone-iodine solution system has good stability and durability during storage, thereby guaranteeing good disinfection and bactericidal effects when applied to affected areas.

[0008] Preferably, the raw materials of the skin and mucous membrane disinfectant also include 0.5%-1.5% glycerol and 0.05%-0.3% dipotassium glycerate.

[0009] By adopting the above technical solution, the addition of glycerin and dipotassium glycerate gives the povidone-iodine solution system a certain skin affinity. Consequently, when applied to the wound, it can reduce the irritation of the povidone-iodine solution system to the human skin and reduce the discomfort caused by disinfection. In addition, it can also enable the disinfectant to adhere better to the skin and mucous membrane surface, increase the residence time of the disinfectant at the wound, and, combined with the slow-release effect of the povidone-iodine solution system, can effectively improve the disinfection effect of the disinfectant to a certain extent.

[0010] Preferably, the surfactant includes at least AEO-9 and 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate.

[0011] By employing the above-mentioned technical solution, the addition of AEO-9 and 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate effectively reduces the surface tension of the disinfectant system, thereby enabling the system to form a relatively homogeneous solution. Simultaneously, AEO-9 and 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate possess certain surface activity, forming a molecular film around povidone-iodine molecules through surfactant adsorption. This creates a protective layer that inhibits particle collisions and sedimentation, thus suppressing the dissociation of iodine from povidone-iodine and reducing the aggregation or volatilization of iodine molecules. Furthermore, we found that the addition of 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate allows the disinfectant to form a more effective surface film after application to the wound, increasing the contact time of the povidone-iodine solution and achieving a good disinfection and sterilization effect while reducing skin irritation.

[0012] Preferably, the raw materials of the skin and mucous membrane disinfectant also include 0.1%-0.3% potassium iodate and 0.05%-0.1% potassium iodide.

[0013] By adopting the above technical solution, the addition of potassium iodate and potassium iodide allows potassium iodate to release iodate ions in the solution, and potassium iodide to release iodide ions in the solution. An appropriate concentration of iodate ions can effectively inhibit the hydrolysis reaction of iodine, and an appropriate concentration of iodide ions can effectively inhibit the hydrolysis process of povidone-iodine.

[0014] Secondly, this application provides a method for preparing a skin and mucous membrane disinfectant, which adopts the following technical solution: A method for preparing a skin and mucous membrane disinfectant includes at least the following process steps: S1. Add an appropriate amount of purified water to the container, and add dipotassium hydrogen phosphate, potassium dihydrogen phosphate, and chlorhexidine acetate to the container in proportion and stir until completely dissolved. S2, Add the surfactant and polyvinylpyrrolidone to the above solution in sequence according to the ratio and stir until completely dissolved; S3, add povidone-iodine and the remaining purified water to the solution treated in S2 according to the proportion, and stir continuously to obtain a homogeneous solution, thus obtaining the skin and mucous membrane disinfectant.

[0015] Preferably, in step S2, glycerol, potassium iodate, and potassium iodide are added in proportion and stirred continuously until completely dissolved; then, before step S3, dipotassium glycerate is added in proportion and stirred until completely dissolved.

[0016] Preferably, after adding povidone-iodine to S3, the stirring direction is alternated between clockwise and counterclockwise, and the stirring speed is not higher than 1000 r / min.

[0017] By employing the above technical solutions, the addition of potassium dihydrogen phosphate and dipotassium hydrogen phosphate can maintain the povidone-iodine solution system within a suitable acidic pH range, effectively reducing the oxidation and volatilization of iodine after its addition. Simultaneously, adding a surfactant before adding povidone-iodine enhances the stability of the solution system. This may be achieved through surfactant adsorption, forming a molecular film around the povidone-iodine molecules, thus creating a protective layer that inhibits particle collisions and sedimentation. This, to some extent, suppresses the dissociation of iodine from povidone-iodine, reducing the aggregation or volatilization of iodine molecules. The addition of polyvinylpyrrolidone (PVP) as an iodine stabilizer allows PPVP to form a relatively stable complex with the dissociated iodine in povidone-iodine through charge transfer, transforming iodine from a volatile free state to a bound state, thereby minimizing the reduction in effective iodine content. Finally, povidone-iodine is added and stirred to dissolve. Alternating clockwise and counter-clockwise stirring ensures good dissolution and a homogeneous solution, reducing iodine loss due to oxidation or volatilization during preparation. Simultaneously, a relatively gentle stirring speed allows for better formation of stable complexes within the povidone-iodine solution, and facilitates the formation of a protective layer around the povidone-iodine molecules by the surfactant components, further minimizing iodine loss and increasing the effective iodine content of the final skin and mucous membrane disinfectant. This also enhances the durability and stability of the povidone-iodine solution during storage, ensuring excellent disinfection and sterilization performance during sterilization processes.

[0018] In summary, this application has the following beneficial effects: The skin and mucous membrane disinfectant of this invention uses povidone-iodine and chlorhexidine acetate as effective bactericidal components. The use of dipotassium hydrogen phosphate and potassium dihydrogen phosphate effectively reduces the loss of effective iodine content in the povidone-iodine solution system. Simultaneously, the addition of surfactants and polyvinylpyrrolidone ensures good stability and durability of the povidone-iodine solution system during storage, thereby guaranteeing good disinfection and sterilization effects when applied to affected areas. Furthermore, the addition of 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate and glycerin gives the disinfectant good skin affinity, allowing it to form a more effective surface film after application to wounds. This increases the contact time of the povidone-iodine solution system at the wound site, achieving good disinfection and sterilization effects while reducing skin irritation. Detailed Implementation

[0019] The present application will be further described in detail below with reference to the embodiments. Example

[0020] Example 1: A skin and mucous membrane disinfectant, prepared from raw materials comprising the following mass percentages: 3% povidone-iodine, 0.02% potassium dihydrogen phosphate, 0.2% dipotassium hydrogen phosphate, 0.02% chlorhexidine acetate, 0.5% glycerol, 0.05% dipotassium glycerate, 1% surfactant, 2% polyvinylpyrrolidone, and the remainder purified water.

[0021] The surfactant used is commercially available AEO-9.

[0022] A method for preparing a skin and mucous membrane disinfectant includes the following process steps: S1. Add 80% purified water to the reaction vessel, and add 0.02% potassium dihydrogen phosphate, 0.2% dipotassium hydrogen phosphate and 0.02% chlorhexidine acetate to the vessel and stir until completely dissolved. S2, add 0.5% glycerol, 1% AEO-9 and 2% polyvinylpyrrolidone to the above solution in sequence and stir until completely dissolved; then add 0.05% dipotassium glycerate in sequence and stir until completely dissolved. S3, add 3% povidone-iodine and the remaining purified water to the solution treated in S2 according to the ratio, and stir continuously to obtain a homogeneous solution, thus obtaining the skin and mucous membrane disinfectant.

[0023] Example 2: A skin and mucous membrane disinfectant, prepared from raw materials comprising the following mass percentages: 5% povidone-iodine, 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate, 0.033% chlorhexidine acetate, 1% glycerol, 0.1% dipotassium glycerate, 2% surfactant, 3% polyvinylpyrrolidone, and the remainder purified water.

[0024] The surfactant used is commercially available AEO-9.

[0025] A method for preparing a skin and mucous membrane disinfectant includes the following process steps: S1. Add 80% purified water to the reaction vessel, and add 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate and 0.033% chlorhexidine acetate to the vessel and stir until completely dissolved. S2, add 1% glycerol, 2% AEO-9 and 3% polyvinylpyrrolidone to the above solution in sequence and stir until completely dissolved; then add 0.1% dipotassium glycerate in proportion and stir until completely dissolved; S3, add 5% povidone-iodine and the remaining purified water to the solution treated in S2 according to the ratio, and stir continuously to obtain a homogeneous solution, thus obtaining the skin and mucous membrane disinfectant.

[0026] Example 3: A skin and mucous membrane disinfectant, prepared from raw materials comprising the following mass percentages: 6% povidone-iodine, 0.1% potassium dihydrogen phosphate, 0.4% dipotassium hydrogen phosphate, 0.06% chlorhexidine acetate, 1.5% glycerol, 0.3% dipotassium glycerate, 3% surfactant, 4% polyvinylpyrrolidone, and the remainder purified water.

[0027] The surfactant used is commercially available AEO-9.

[0028] A method for preparing a skin and mucous membrane disinfectant includes the following process steps: S1. Add 80% purified water to the reaction vessel, and add 0.1% potassium dihydrogen phosphate, 0.4% dipotassium hydrogen phosphate and 0.06% chlorhexidine acetate to the vessel and stir until completely dissolved. S2, add 1.5% glycerol, 3% AEO-9 and 4% polyvinylpyrrolidone to the above solution in sequence and stir until completely dissolved; then add 0.3% dipotassium glycerate in proportion and stir until completely dissolved. S3, add 6% povidone-iodine and the remaining purified water to the solution treated in S2 according to the ratio, and stir continuously to obtain a homogeneous solution, thus obtaining the skin and mucous membrane disinfectant.

[0029] Example 4: A skin and mucous membrane disinfectant, prepared from raw materials comprising the following mass percentages: 5% povidone-iodine, 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate, 0.033% chlorhexidine acetate, 1% glycerol, 0.1% dipotassium glycerate, 2% surfactant, 3% polyvinylpyrrolidone, and the balance being purified water.

[0030] The surfactants used are commercially available AEO-9 and 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate, with the ratio of 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate to AEO-9 being 1.5:1.

[0031] A method for preparing a skin and mucous membrane disinfectant includes the following process steps: S1. Add 80% purified water to the reaction vessel, and add 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate and 0.033% chlorhexidine acetate to the vessel and stir until completely dissolved. S2, add 1% glycerol, 2% AEO-9 and 3% polyvinylpyrrolidone to the above solution in sequence and stir until completely dissolved; then add 0.1% dipotassium glycerate in proportion and stir until completely dissolved; S3, add 5% povidone-iodine and the remaining purified water to the solution treated in S2 according to the ratio, and stir continuously to obtain a homogeneous solution, thus obtaining the skin and mucous membrane disinfectant.

[0032] Example 5: A skin and mucous membrane disinfectant, prepared from raw materials comprising the following mass percentages: 5% povidone-iodine, 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate, 0.033% chlorhexidine acetate, 1% glycerol, 0.1% dipotassium glycerate, 0.2% potassium iodate, 0.08% potassium iodide, 2% surfactant, 3% polyvinylpyrrolidone, and the balance being purified water.

[0033] The surfactants used are commercially available AEO-9 and 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate, with the ratio of 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate to AEO-9 being 1.5:1.

[0034] A method for preparing a skin and mucous membrane disinfectant includes the following process steps: S1. Add 80% purified water to the reaction vessel, and add 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate and 0.033% chlorhexidine acetate to the vessel and stir until completely dissolved. S2, add 1% glycerol, 0.2% potassium iodate, 0.08% potassium iodide, 2% AEO-9 and 3% polyvinylpyrrolidone to the above solution in sequence and stir until completely dissolved; then add 0.1% dipotassium glycerate in proportion and stir until completely dissolved. S3, add 5% povidone-iodine and the remaining purified water to the solution treated by S2 according to the proportion, and stir continuously to obtain a homogeneous solution. In S3, after adding povidone-iodine, the stirring direction is alternately clockwise and counterclockwise, specifically, stir clockwise for 3 minutes and then counterclockwise for 3 minutes, with a stirring speed of 500 r / min, to obtain the skin and mucous membrane disinfectant.

[0035] Example 6: A skin and mucous membrane disinfectant, prepared from raw materials comprising the following mass percentages: 5% povidone-iodine, 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate, 0.033% chlorhexidine acetate, 1% glycerol, 0.1% dipotassium glycerate, 0.2% potassium iodate, 0.08% potassium iodide, 2% surfactant, 3% polyvinylpyrrolidone, and the balance being purified water.

[0036] The surfactants used are commercially available AEO-9 and 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate, with the ratio of 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate to AEO-9 being 1.1:1.

[0037] A method for preparing a skin and mucous membrane disinfectant includes the following process steps: S1. Add 80% purified water to the reaction vessel, and add 0.03% potassium dihydrogen phosphate, 0.3% dipotassium hydrogen phosphate and 0.033% chlorhexidine acetate to the vessel and stir until completely dissolved. S2, add 1% glycerol, 0.2% potassium iodate, 0.08% potassium iodide, 2% AEO-9 and 3% polyvinylpyrrolidone to the above solution in sequence and stir until completely dissolved; then add 0.1% dipotassium glycerate in proportion and stir until completely dissolved. S3, add 5% povidone-iodine and the remaining purified water to the solution treated by S2 according to the proportion, and stir continuously to obtain a homogeneous solution. In S3, after adding povidone-iodine, the stirring direction is alternately clockwise and counterclockwise, specifically, stir clockwise for 3 minutes and then counterclockwise for 3 minutes, with a stirring speed of 500 r / min, to obtain the skin and mucous membrane disinfectant.

[0038] Comparative Example Comparative Example 1: The difference between Comparative Example 1 and Example 1 is that no surfactant and polyvinylpyrrolidone were added.

[0039] Performance testing 1. Disinfection and sterilization performance The performance of the skin and mucous membrane disinfectants prepared in Examples 1-6 was tested according to Appendix A of GB 27951-2011 "Hygienic Requirements for Skin Disinfectants". The test environment temperature was 26°C and the relative humidity was 60%.

[0040] The disinfection and sterilization performance results of the skin and mucous membrane disinfectant solutions prepared in Examples 1-6 are shown in the table below.

[0041]

[0042] Based on Examples 1-6 and the disinfection and sterilization performance data tests, it can be seen that the skin and mucous membrane disinfectant prepared by the present invention has good disinfection and sterilization performance, can effectively eliminate aerobic-anaerobic bacteria and fungi, and can be well applied in various fields that require disinfection and sterilization.

[0043] 2. Skin and mucous membrane disinfection performance test Test strain: Escherichia coli 8099, provided by the Institute of Microbiology, Chinese Academy of Sciences, 5th generation nutrient broth culture. Culture medium: Nutrient broth containing 0.9% lecithin, 3% Tween-80, 1% sodium thiosulfate, and 0.1% histidine.

[0044] After culturing the test strain in a culture medium, observing and recording the growth of bacterial colonies, the colonies were transferred to the skin surface tissue as test tissue.

[0045] Take 0.20g of cotton ball, soak it in the skin and mucous membrane disinfectant prepared in Examples 1-6 and Comparative Example 1, wipe the treated area twice, take a sample after 1 minute, and observe the number of residual bacteria on the treated skin. The test temperature is 20-21℃ and the relative humidity is 30%-32%.

[0046]

[0047] Based on Examples 1-6 and Comparative Example 1, and combined with performance data testing, it can be seen that the skin and mucous membrane disinfectant prepared by the present invention has excellent disinfection and sterilization effects, thereby ensuring that the disinfectant has good disinfection and sterilization effects when applied to the affected area.

[0048] As can be seen from Examples 1-3 and Comparative Example 1, combined with performance data testing, the skin and mucous membrane disinfectant of the present invention uses povidone-iodine and chlorhexidine acetate as effective bactericidal components. The loss of effective iodine content in the povidone-iodine solution system is effectively reduced by dipotassium hydrogen phosphate and potassium dihydrogen phosphate. At the same time, the addition of surfactants and polyvinylpyrrolidone makes the povidone-iodine solution system have good stability and durability during storage, thereby ensuring that the disinfectant can have a better disinfection and bactericidal effect when applied to the affected area.

[0049] Through Examples 2, 4-6, and Comparative Example 1, combined with performance data testing, it can be seen that the addition of glycerol and dipotassium glycerate enables the disinfectant to adhere better to the skin and mucous membrane surface, increasing the residence time of the disinfectant at the wound site. Combined with the sustained-release effect of the povidone-iodine solution system, and the addition of 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate, the disinfectant can more effectively form a surface film after acting on the wound surface, thus effectively increasing the action time of the povidone-iodine solution system at the wound site and achieving a good disinfection and sterilization effect.

[0050] In addition, alternating clockwise and counterclockwise stirring allows povidone-iodine to dissolve better in the system to form a homogeneous solution. Combined with the surfactant and polyvinylpyrrolidone components, it can effectively prevent the loss of effective iodine content in the povidone-iodine solution system, thus giving the skin and mucous membrane disinfectant excellent disinfection and sterilization effects.

[0051] This specific embodiment is merely an explanation of this application and is not intended to limit it. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they fall within the scope of the claims of this application.

Claims

1. A skin and mucous membrane disinfectant, characterized in that, It is prepared from raw materials including the following components: 3%-6% povidone-iodine, 0.02%-0.1% potassium dihydrogen phosphate, 0.2%-0.4% dipotassium hydrogen phosphate, 0.02%-0.06% chlorhexidine acetate, 1%-3% surfactant, 2%-4% polyvinylpyrrolidone, and the balance being purified water.

2. The skin and mucous membrane disinfectant according to claim 1, characterized in that, The raw materials of the skin and mucous membrane disinfectant also include 0.5%-1.5% glycerol and 0.05%-0.3% dipotassium glycerate.

3. The skin and mucous membrane disinfectant according to claim 1, characterized in that, The surfactant includes at least AEO-9 and 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate.

4. The skin and mucous membrane disinfectant according to claim 3, characterized in that: In the surfactant, the ratio of 2,2,4-trimethyl-1,3-pentanediol monoisobutyrate to AEO-9 is not less than 1.5:

1.

5. The skin and mucous membrane disinfectant according to claim 1, characterized in that: The raw materials of the skin and mucous membrane disinfectant also include 0.1%-0.3% potassium iodate and 0.05%-0.1% potassium iodide.

6. The preparation process of the skin and mucous membrane disinfectant according to any one of claims 1-5, characterized in that, It should include at least the following process steps: S1. Add an appropriate amount of purified water to the container, and add dipotassium hydrogen phosphate, potassium dihydrogen phosphate, and chlorhexidine acetate to the container in proportion and stir until completely dissolved. S2, Add the surfactant and polyvinylpyrrolidone to the above solution in sequence according to the ratio and stir until completely dissolved; S3, add povidone-iodine and the remaining purified water to the solution treated in S2 according to the proportion, and stir continuously to obtain a homogeneous solution, thus obtaining the skin and mucous membrane disinfectant.

7. The preparation process of a skin and mucous membrane disinfectant according to claim 6, characterized in that, In S2, add glycerol, potassium iodate, and potassium iodide in proportion and stir continuously until completely dissolved; then before proceeding to S3, add dipotassium glycerate in proportion and stir until completely dissolved.

8. The preparation process of a skin and mucous membrane disinfectant according to claim 6, characterized in that, After adding povidone-iodine to S3, stir in alternating clockwise and counterclockwise directions, while keeping the stirring speed below 1000 r / min.

Images